Piper Jaffray

CureVac to Present at the 31st Annual Piper Jaffray Healthcare Conference

Retrieved on: 
Wednesday, November 20, 2019
Health, Life sciences, Articles, Pharmacy, Boehringer Ingelheim, CureVac, Eli Lilly and Company, Biopharmaceutical, Piper Jaffray, Boehringer, Pharmaceutical industry

TBINGEN, Germany and BOSTON, Nov. 20, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Chief Executive Officer, Dan Menichella, will present a corporate overview at the 31st Annual Piper Jaffray Healthcare Conference in New York on December 3, 2019.

Key Points: 
  • TBINGEN, Germany and BOSTON, Nov. 20, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Chief Executive Officer, Dan Menichella, will present a corporate overview at the 31st Annual Piper Jaffray Healthcare Conference in New York on December 3, 2019.
  • Interested parties can contact Thomas Hoffmann ( [email protected] ) to schedule a meeting with CureVac representatives during the conference.
  • The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines.
  • CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others.

Illumina to Webcast Upcoming Investor Conference Presentations

Retrieved on: 
Wednesday, November 20, 2019
Health, Medical devices, Genetics, Research, Science, Pharmaceutical, Biotechnology, DNA sequencing, Illumina, Inc., Microarrays, Evercore, Piper Jaffray, Companies, Illumina, Biotechnology, Biology

Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.

Key Points: 
  • Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
  • Evercore ISI HealthCONx Conference in Boston, MA
    Piper Jaffray Annual Healthcare Conference in New York, NY
    The live webcasts can be accessed in the Investor Relations section of Illumina's web site under the "company" tab at www.illumina.com .
  • A replay of the presentations will be posted on Illuminas website after the event and will be available for at least 30 days following.
  • Illumina is improving human health by unlocking the power of the genome.

Oppenheimer & Co. Inc. Continues Expansion of Technology Investment Banking Practice with New Managing Director

Retrieved on: 
Wednesday, November 20, 2019
Piper Jaffray, U.S. Bancorp, Application software, Enterprise software, Business, Companies

Livadariu will be located in Denver, CO and reports to Robin Graham, Head of Technology, Media and Communications Investment Banking.

Key Points: 
  • Livadariu will be located in Denver, CO and reports to Robin Graham, Head of Technology, Media and Communications Investment Banking.
  • "Andy's considerable experience providing strategic advice to application software companies, particularly in the human capital management and customer experience sectors, is a strong complement to our current senior software banking team."
  • Livadariu joins Oppenheimer with nearly twenty years of experience advising clients across the broader technology and enterprise application software market.
  • Previously, Livadariu was with Piper Jaffray where he covered application software and led the human capital management practice.

Caris Life Sciences to Present at 31st Annual Piper Jaffray Healthcare Conference

Retrieved on: 
Wednesday, November 20, 2019
Caris, Teledyne CARIS, Piper Jaffray, Precision medicine, Companies

Mr. Brille will present a corporate overview and discuss recent expansion and development progress that positions the Company to further extend its leadership in precision medicine.

Key Points: 
  • Mr. Brille will present a corporate overview and discuss recent expansion and development progress that positions the Company to further extend its leadership in precision medicine.
  • Investors attending the conference who would like to schedule a one-on-one meeting with Caris executives may do so by contacting their Piper Jaffray representative.
  • Caris Life Sciences is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation.
  • Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets.

Intersect ENT to Present at the 31st Annual Piper Jaffray Healthcare Conference

Retrieved on: 
Tuesday, November 19, 2019
Biotechnology, Pharmaceutical, Health, Medical devices, Intersect ENT, Piper Jaffray, ENT, Companies

Intersect ENT, Inc. (NASDAQ: XENT ) today announced that management will participate in the 31st Annual Piper Jaffray Healthcare Conference on December 4 at the Lotte New York Palace Hotel in New York City, and will present in a session at 4:30 pm ET.

Key Points: 
  • Intersect ENT, Inc. (NASDAQ: XENT ) today announced that management will participate in the 31st Annual Piper Jaffray Healthcare Conference on December 4 at the Lotte New York Palace Hotel in New York City, and will present in a session at 4:30 pm ET.
  • A replay of the session will be available via the investors section of the companys website at www.intersectENT.com .
  • Intersect ENT is dedicated to transforming ear, nose and throat care by providing innovative, clinically meaningful therapies to physicians and patients.
  • The companys steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease.

NextCure Announces Closing of Public Offering

Retrieved on: 
Tuesday, November 19, 2019
Finance, Money, Economy, Piper Jaffray, U.S. Bancorp, Initial public offering, Public offering, Offering, Underwriting, NASDAQ

BELTSVILLE, Md., Nov. 19, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the closing of its public offering of 4,077,192 shares of its common stock at a public offering price of $36.75 per share.

Key Points: 
  • BELTSVILLE, Md., Nov. 19, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the closing of its public offering of 4,077,192 shares of its common stock at a public offering price of $36.75 per share.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $150 million.
  • Morgan Stanley, BofA Securities and Piper Jaffray & Co. acted as joint book-running managers for the offering.
  • Investor Inquiries Timothy Mayer, Ph.D. NextCure, Inc. Chief Operating Officer (240) 762-6486 [email protected] Media Inquiries Shai Biran, Ph.D. MacDougall (781) 235-3060 [email protected]

LivaNova to Present at the Berenberg and Piper Jaffray Conferences

Retrieved on: 
Tuesday, November 19, 2019
Cardiology, Biotechnology, Surgery, Health, FDA, Medical devices, Hospitals, Clinical trials, LivaNova, Piper Jaffray, Livanov, Jaffray, Berenberg, Companies, Humans

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston, Chief Financial Officer, will participate in discussions at the Berenberg European Conference 2019 in London and at the Piper Jaffray 31st Annual Healthcare Conference in New York.

Key Points: 
  • LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston, Chief Financial Officer, will participate in discussions at the Berenberg European Conference 2019 in London and at the Piper Jaffray 31st Annual Healthcare Conference in New York.
  • The Piper Jaffray discussion will be available to all interested parties through a live audiocast accessible via the Investor Relations section of the LivaNova website at www.livanova.com .
  • Replays of the webcast will be available on the LivaNova website within 24 hours after the live presentation for 90 days after the event.
  • LivaNova operates as two businesses: Cardiovascular and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.), respectively.

Progenity to Present at Piper Jaffray 31st Annual Healthcare Conference

Retrieved on: 
Tuesday, November 19, 2019
Biotechnology, Health, Oncology, Other Health, Investment banks, Piper Jaffray, U.S. Bancorp, Companies

Progenity, Inc. announced today that the company will be participating in the Piper Jaffray 31st Annual Healthcare Conference in New York, December 3-5.

Key Points: 
  • Progenity, Inc. announced today that the company will be participating in the Piper Jaffray 31st Annual Healthcare Conference in New York, December 3-5.
  • Progenitys chief executive officer, Harry Stylli, PhD, will present a corporate overview on Wednesday, December 4, from 1:10 PM to 1:30 PM ET.
  • Dr. Stylli and Eric dEsparbes, chief financial officer, will also participate in one-on-one meetings with investors.
  • Progenity, Inc., is a privately held, biotechnology company with the mission of transforming healthcare to be more precise and personal.

Mallinckrodt to Present at Piper Jaffray Annual Healthcare Conference

Retrieved on: 
Tuesday, November 19, 2019
Life sciences, Articles, Biotechnology, Mallinckrodt, Piper Jaffray, MNK, Biopharmaceutical

STAINES-UPON-THAMES, United Kingdom, Nov. 19, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, Dec. 3, 2019, at the Piper Jaffray Annual Healthcare Conference at the Lotte New York Palace, 455 Madison Ave, New York.

Key Points: 
  • STAINES-UPON-THAMES, United Kingdom, Nov. 19, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, Dec. 3, 2019, at the Piper Jaffray Annual Healthcare Conference at the Lotte New York Palace, 455 Madison Ave, New York.
  • Individuals who cannot attend the meeting in person can find webcast information at: http://www.mallinckrodt.com/investors .
  • Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies.
  • Mallinckrodtuses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information.

Matinas BioPharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

Retrieved on: 
Monday, November 18, 2019
Piper Jaffray, U.S. Bancorp

BEDMINSTER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a company overview, as well as host investor meetings, at the 31st Annual Piper Jaffray Healthcare Conference.

Key Points: 
  • BEDMINSTER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a company overview, as well as host investor meetings, at the 31st Annual Piper Jaffray Healthcare Conference.
  • Place: Lotte New York Palace Hotel, New York
    Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.
  • Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions.
  • Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.